Determine the necessary mass, volume, or concentration for preparing a solution.
This is a demo store. No orders will be fulfilled.
| SKU | Size | Availability |
Price | Qty |
|---|---|---|---|---|
|
F650409-1mg
|
1mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$38.90
|
|
|
F650409-5mg
|
5mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$93.90
|
|
|
F650409-10mg
|
10mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$139.90
|
|
|
F650409-25mg
|
25mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$309.90
|
|
|
F650409-50mg
|
50mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$549.90
|
|
| Synonyms | 7-benzyl-2,3-dihydroxy-6-methyl-4-propyl-naphthalene-1-carboxylic Acid | 7-benzyl-2,3-dihydroxy-6-methyl-4-propylnaphthalene-1-carboxylic acid | SCHEMBL233361 | NCGC00249596-01 | BDBM50066974 | FX 11 | LDHA Inhibitor FX11 | LDHA Inhibitor, 3 | HY-16214 | |
|---|---|
| Specifications & Purity | ≥98% |
| Biochemical and Physiological Mechanisms | FX-11 is a potent, selective, reversible and competitive lactate dehydrogenase A (LDHA) inhibitor, with a Ki of 8 μM. FX-11 reduces ATP levels and induces oxidative stress, ROS production and cell death. FX-11 shows antitumor activity in lymphoma and panc |
| Storage Temp | Store at -20°C |
| Shipped In |
Ice chest + Ice pads This product requires cold chain shipping. Ground and other economy services are not available. |
| Product Description |
FX-11 is a potent, selective, reversible and competitive lactate dehydrogenase A ( LDHA ) specific inhibitor, with a K i of 8 μM. FX-11 can effectively activate PKM2 (pyruvate kinase M2). FX-11 reduces ATP levels and induces oxidative stress, ROS production and cell death. FX-11 shows antitumor activity in lymphoma and pancreatic cancer xenografts In Vitro FX-11 (9 μM, 24-48 h) shows activation of AMP kinase and phosphorylation of its substrate acetyl-CoA carboxylase. ?\nFX-11 (0-100 μM, 72 h) inhibits cell proliferation in BxPc-3 and MIA PaCa-2 cells. ?\nFX-11 inhibits glycolysis and alters cellular energy metabolism in P493 cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot AnalysisCell Line: P493 cells Concentration: 9 μM Incubation Time: 24 h, 48 h Result: Showed a decrease in ATP levels, accompanied by activation of AMP kinase and phosphorylation of its substrate acetyl-CoA carboxylase. Cell Proliferation AssayCell Line: BxPc-3 and MIA PaCa-2 cells Concentration: 0-100 µM Incubation Time: 72 h Result: Reduced cell metabolic activity in a concentration-dependent manner, showed a significant reduction in cell proliferation, with IC 50 values of 49.27 µM and 60.54 µM for BxPc-3 and MIA PaCa-2 cells, respectively. In Vivo FX-11 (42 μg/mouse; IP, daily for 10-14 days) inhibits P493 tumor growth. ?\nFX-11 (0-2 mg/kg, IP, daily, for 3 weeks) significantly delays tumor growth. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male SCID mice and RH-Foxn1nu mice (human P493 B-cell xenografts)Dosage: 42 µg/mouse (2.1 mg/kg) Administration: IP; daily for 10-14 days Result: Resulted in a remarkable inhibition of tumor growth, inhibited tumor xenograft progression. Animal Model: Immunocompromised CD-1 mice (6-8 weeks; 20-25 g, n=5 per group)Dosage: 2 mg/kg, 1 mg/kg+15 mg/kg TEPP-46, 2 mg/kg+30 mg/kg TEPP-46 Administration: IP (100 µL), daily, for 3 weeks Result: Significantly lowered LDHA activity in plasma and tumor lysates; significantly lowered the expression of the proliferation marker Ki-67; significantly decreased proliferation indices were observed in tumor sections; significantly delayed tumor growth. Form:Solid IC50& Target:IC50: 23.3 μM (LDHA in HeLa cell) |
Taxonomy Tree
| Kingdom | Organic compounds |
|---|---|
| Superclass | Benzenoids |
| Class | Naphthalenes |
| Subclass | Naphthalenecarboxylic acids and derivatives |
| Intermediate Tree Nodes | Not available |
| Direct Parent | Naphthalenecarboxylic acids |
| Alternative Parents | Naphthols and derivatives Salicylic acid and derivatives Phenols Vinylogous acids Carboxylic acids Organooxygen compounds Organic oxides Hydrocarbon derivatives |
| Molecular Framework | Aromatic homopolycyclic compounds |
| Substituents | 1-naphthalenecarboxylic acid - 2-naphthol - Dihydroxybenzoic acid - Salicylic acid or derivatives - Hydroxybenzoic acid - Phenol - Monocyclic benzene moiety - Vinylogous acid - Carboxylic acid - Carboxylic acid derivative - Organic oxygen compound - Organic oxide - Hydrocarbon derivative - Organooxygen compound - Aromatic homopolycyclic compound |
| Description | This compound belongs to the class of organic compounds known as naphthalenecarboxylic acids. These are compounds containing a naphthalene moiety, which bears a carboxylic acid group one or more positions. Naphthalene is a bicyclic compound that is made up of two fused benzene ring. |
| External Descriptors | Not available |
|
|
|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
| IUPAC Name | 7-benzyl-2,3-dihydroxy-6-methyl-4-propylnaphthalene-1-carboxylic acid |
|---|---|
| INCHI | InChI=1S/C22H22O4/c1-3-7-16-17-10-13(2)15(11-14-8-5-4-6-9-14)12-18(17)19(22(25)26)21(24)20(16)23/h4-6,8-10,12,23-24H,3,7,11H2,1-2H3,(H,25,26) |
| InChIKey | LVPYVYFMCKYFCZ-UHFFFAOYSA-N |
| Smiles | CCCC1=C(C(=C(C2=C1C=C(C(=C2)CC3=CC=CC=C3)C)C(=O)O)O)O |
| Isomeric SMILES | CCCC1=C(C(=C(C2=C1C=C(C(=C2)CC3=CC=CC=C3)C)C(=O)O)O)O |
| PubChem CID | 10498042 |
| Molecular Weight | 350.41 |
Find and download the COA for your product by matching the lot number on the packaging.
| Lot Number | Certificate Type | Date | Item |
|---|---|---|---|
| Certificate of Analysis | Apr 09, 2024 | F650409 | |
| Certificate of Analysis | Apr 09, 2024 | F650409 | |
| Certificate of Analysis | Apr 09, 2024 | F650409 | |
| Certificate of Analysis | Apr 09, 2024 | F650409 | |
| Certificate of Analysis | Apr 09, 2024 | F650409 |
| Solubility | DMSO : 250 mg/mL (713.45 mM; Need ultrasonic) |
|---|---|
| Molecular Weight | 350.400 g/mol |
| XLogP3 | 6.200 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 5 |
| Exact Mass | 350.152 Da |
| Monoisotopic Mass | 350.152 Da |
| Topological Polar Surface Area | 77.800 Ų |
| Heavy Atom Count | 26 |
| Formal Charge | 0 |
| Complexity | 473.000 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| The total count of all stereochemical bonds | 0 |
| Covalently-Bonded Unit Count | 1 |
Starting at $132.90